(Q37848476)

24 August 2017

1 reference

title

Pharmacogenetics of alcohol, nicotine and drug addiction treatments (English)

1 reference

24 August 2017

0 references

0 references

4

Andreas Heinz

1 reference

24 August 2017

Jessica E Sturgess

1

1 reference

24 August 2017

Tony P George

series ordinal

2

1 reference

24 August 2017

James L Kennedy

series ordinal

3

1 reference

24 August 2017

Daniel J Müller

series ordinal

5

1 reference

24 August 2017

language of work or name

1 reference

1 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

16

1 reference

24 August 2017

3

1 reference

24 August 2017

357-376

1 reference

An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study

24 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Pharmacogenomics: the promise of personalized medicine for CNS disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

DBH gene variants that cause low plasma dopamine beta hydroxylase with or without a severe orthostatic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Nicotine replacement therapy for long-term smoking cessation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Multiple genetic tests for susceptibility to smoking do not outperform simple family history

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Human neuronal nicotinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Influence of genetic variations of ethanol-metabolizing enzymes on phenotypes of alcohol-related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Nicotinic receptors in the brain: correlating physiology with function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Nicotine addiction: a pediatric disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

A genotype-controlled analysis of plasma dopamine beta-hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences in noradrenergic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Neuroscience of addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Treatment of tobacco dependence: integrating recent progress into practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Changes in food reward following smoking cessation: a pharmacogenetic investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Genetics and smoking cessation improving outcomes in smokers at risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Pharmacogenetic investigation of smoking cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Influence of the dopamine D2 receptor (DRD2) exon 8 genotype on efficacy of tiapride and clinical outcome of alcohol withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

What we know: findings that every theory of schizophrenia should explain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Pharmacogenetics of psychotropic drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Injection drug use and crack cocaine smoking: independent and dual risk behaviors for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Genetic moderators of naltrexone's effects on alcohol cue reactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Actual Causes of Death in the United States, 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

The clinical utility of genetic tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Association of the mu-opioid receptor gene with smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Smoking cessation, weight gain, and DRD4 -521 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Pharmacogenetics and nicotine addiction treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

A genetic determinant of the striatal dopamine response to alcohol in men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Nicotinic receptors in the development and modulation of CNS synapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Current and emerging pharmacotherapies for treating tobacco dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Translating emerging research on the genetics of smoking into clinical practice: ethical and social considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Molecular genetics of successful smoking cessation: convergent genome-wide association study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Naltrexone Pharmacology, Pharmacokinetics, and Metabolism: Current Status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Effectiveness of smoking cessation therapies: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

Stereoselective Block of hERG Channel by (S)-Methadone and QT Interval Prolongation in CYP2B6 Slow Metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1369-1600.2010.00287.X

10.1111/J.1369-1600.2010.00287.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference